| PARP Inhibition for Gliomas (PI-4G or π4g) (NCT05297864) | University of Oklahoma | 2022-06-09 |
| Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma (NCT05045027) | Jonsson Comprehensive Cancer Center | 2021-09-01 |
| Personalized Vaccine for Patients With Recurrent Malignant Glioma (NCT04943718) | Xuanwu Hospital, Beijing | 2021-07-15 |
| A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (NCT04794972) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-04-14 |
| Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd (NCT04740190) | The University of Hong Kong | 2021-01-01 |
| Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome (NCT04562077) | Assiut University | 2020-10-01 |
| Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) (NCT04164901) | Institut de Recherches Internationales Servier | 2020-01-05 |
| A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas (NCT04089449) | Prelude Therapeutics | 2019-11-06 |
| Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations (NCT03212274) | National Cancer Institute (NCI) | 2019-01-30 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994) | National Cancer Institute (NCI) | 2018-11-14 |
| Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (NCT03389230) | City of Hope Medical Center | 2018-08-14 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250) | National Cancer Institute (NCI) | 2018-08-13 |
| Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas (NCT04216550) | The First Affiliated Hospital of Zhengzhou University | 2018-01-01 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678) | National Cancer Institute (NCI) | 2017-11-28 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) (NCT03233204) | National Cancer Institute (NCI) | 2017-09-14 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704) | National Cancer Institute (NCI) | 2017-08-23 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620) | National Cancer Institute (NCI) | 2017-07-31 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma (NCT01580969) | University of Utah | 2012-07-06 |
| Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors (NCT01324635) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-05-01 |